Euan Ashley
About Euan Ashley
Euan Ashley is a prominent figure in the fields of medicine and genomics, serving as the Founder of Deepcell, Inc. and holding multiple leadership roles at Stanford Health Care and Stanford University.
Work at Deepcell
Euan Ashley is the Founder of Deepcell, Inc., a biotechnology company established in 2016. The company focuses on advancements in genomics and personalized medicine. Deepcell was spun out of Stanford University in 2017, reflecting Ashley's commitment to translating scientific research into practical applications. He co-founded Deepcell alongside Maddison Masaeli and Mahyar Salek. Under his leadership, Deepcell has aimed to innovate in the field of cellular analysis and diagnostics.
Education and Expertise
Euan Ashley holds a Bachelor's Degree in Physiology from the University of Glasgow, where he studied from 1989 to 1993. He later earned a Doctor of Medicine (MB ChB) from the same university between 1993 and 1996. He pursued further education at the University of Oxford, obtaining a Doctor of Philosophy (Ph.D.) in Cardiovascular Science from 2002 to 2005. His extensive educational background underpins his expertise in medicine, genetics, and biomedical data science.
Background
Euan Ashley has a diverse background in medicine and biotechnology. He has served as Medical Director of Clinical Genomics at Stanford Health Care since 2014 and has been the Founding Director of the Center for Inherited Cardiovascular Disease since 2009. Additionally, he has held a professorship at Stanford University since 2006, where he teaches medicine, genetics, and biomedical data science. His roles reflect a strong commitment to advancing healthcare through genomics.
Achievements
Euan Ashley authored 'The Genome Odyssey,' a book that discusses the impact of genomics on medicine and society. He has also been involved in various leadership roles, including serving as Non-Executive Director at AstraZeneca since 2020 and as Co-Director of the Stanford Medicine Catalyst since 2019. His contributions to the field of genomics and personalized medicine have been recognized through his founding of multiple biotechnology companies, including Personalis, Inc. and Silicon Valley Exercise Analytics (Svexa).